WO2004037828A1 - 光学活性なスルホキシドの製造法 - Google Patents
光学活性なスルホキシドの製造法 Download PDFInfo
- Publication number
- WO2004037828A1 WO2004037828A1 PCT/JP2003/013495 JP0313495W WO2004037828A1 WO 2004037828 A1 WO2004037828 A1 WO 2004037828A1 JP 0313495 W JP0313495 W JP 0313495W WO 2004037828 A1 WO2004037828 A1 WO 2004037828A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- optically active
- titanium
- monotartrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Definitions
- the present invention relates to a method for producing an optically active cyclic sulfoxide, which is an intermediate for synthesizing an excellent neurokinin receptor antagonist ( ⁇ 0987269).
- a cyclic sulfoxide in which the asymmetric oxidizing agent is used, a cyclic sulfoxide can be obtained with a high yield (95%) and a high engineering nathanoma excess (96%). Since the oxidizing agent is expensive, it is an equivalent reaction, and it is difficult to recover it, it is not suitable for industrial production.
- the present inventors have intensively studied an industrial production method of cyclic sulfoxides in order to solve these problems.
- a complex of an optically active tartaric acid diester and a titanium (IV) alkoxide was used as an asymmetric catalyst, and a specific oxidizing agent (cumene hydroxyperoxide or isopropyl) was used in the presence of alcohol, water or a mixture of alcohol and water.
- Oxidation reaction using cumyl hydroperoxide gives cyclic sulfoxide with high yield (90-95%) and high engineering nanthoma excess (87-89% or more).
- the inventors have found that the present invention has been completed.
- the present invention has been completed. The present invention
- G 1 represents a C 6 alkylene group
- Ar represents a C 6 —C 1 Q 7 reel group which may be substituted with a group selected from a substituent group, or a substituent group.
- the substituent group ⁇ is a compound having one (: 6 alkyl groups, Ci—Ce alkoxy groups and octylogen atom) in an inert solvent in the presence of alcohol, water or a mixture of water and alcohol.
- a compound of the general formula (1) characterized in that, in the presence of a complex of an optically active tartaric acid diester and a titanium (IV) alkoxide, cumene hydroperoxide or peroxyl isoprylcumylhydride is allowed to act.
- R 2 represents a hydrogen atom or the same group as defined for R 1
- * represents an asymmetric center.
- Ar is a phenyl group or a phenyl group substituted with one or two groups selected from the group consisting of a fluorine atom, a chlorine atom, methyl, ethyl, methoxy and ethoxy.
- Ar is a phenyl group
- R 1 is, C, - C 4 Arukanoiru, triflumizole Ruo b acetyl, methoxy ⁇ cetyl, Benzoiru, 1 one-naphthoyl, 2-naphthoyl, Anisoiru, nitro base Nzoiru one C 4 alkoxy force Ruponiru, 2, 2, 2-Trichloroethoxycarbonyl, triethylsilylmethoxycarbonyl, 2- (trimethylsilyl) ethoxycarbonyl, butylcarbonyl, aryloxycarbonyl, benzyloxycarbonyl, or nitrobenzyl
- titanium (IV) alkoxide is titanium (IV) methoxide, titanium (IV) ethoxide, titanium (IV) propoxide or titanium (IV) isopropoxide.
- Optically active diester of tartaric acid is (+) — or (I) dimethyl monotartrate, (+) — or (—) — Getyl tartrate, (+) — Young (1) Diisop monotartrate (+) — Or (1) dibutyl monotartrate, or (+) — or (1) di-tert-butyl tartrate,
- optically active diester tartrate is (+) — or (I) getyl monotartrate, or (+) — or (—) — diisopropyl tartrate,
- optically active ditartaric acid diester is (+) — or (—) diisopropate monotartrate pill
- optical resolving agent used in the optical resolution is an optically active sulfonic acid or an optically active carboxylic acid
- optical resolving agent used in the optical resolution is (+) — or (1) camphor-10-sulfonic acid, (+) — or (1) monotartaric acid, (+) — or (—) diacetyl. Tartaric acid, (+) — or (-) dibenzoyltartaric acid, (+) — or
- the compound having the general formula (1) is a compound having an S configuration
- the optically active ditartaric acid diester is (1) dimethyl monotartrate, (1) getyl tartrate, (1) diisopropyl tartrate, (1) dibutyl tartrate or (-) di-tert-butyl monotartrate
- the optical resolving agent used for optical resolution is (1) camphor-1 10-sulfonic acid, (+)-tartaric acid, (+) ) —Dibenzoyltartaric acid or (+) — mandelic acid
- optically active ditartrate is (-) getyl monotartrate or (-)-diisopropyl tartrate
- optically active tartaric acid diester is (1) diisopropyl monotartrate.
- G 1 represents a C i —C 6 alkylene group
- Ar represents a C 6 —C 1 Q aryl group which may be substituted with a group selected from the substituent group ⁇ , or a substituent
- the substituent group ⁇ is C— C 6 alkyl group
- R 3 represents a hydroxyl group, CI- C 4 alkoxy group, CI- C 4 1 to 3 selected from halogenated alkyl group and tetrazolyl
- R 4 represents a phenyl group substituted with 1 or 2 halogen atoms
- n represents 1 or 2
- * represents an asymmetric center.
- step A is a general formula (2)
- R 1 represents a protecting group for an amino group.
- R 1 represents a protecting group for an amino group.
- step B comprises removing R 2 when R 2 of the compound (1) obtained in step A is a protecting group for an amino group, Compound (1) where R 2 is a hydrogen atom and general formula (3)
- Ar is a phenyl group
- R 1 is trifluoroacetyl, methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl, benzyloxycarbonyl,
- Y is a halogen atom, a lower alkenyl sulfonyloxy group, a halogeno lower alkane sulfonyloxy group or an arylsulfonyloxy group,
- R 3 is 3,5-bis (trifluoromethyl) phenyl, 3,4,5-trimethoxyphenyl, 3-hydroxy-4,5-dimethoxyphenyl, 4-hydroxy-1,3,5-dimethoxyphenyl or 2-methoxy-5- (1-tetrazolyl) phenyl, and
- R 4 is a phenyl group substituted with one or two fluorine atoms or chlorine atoms.
- Ci—C 6 alkylene group in the definition of G 1 includes, for example, methylene, ethylene, trimethylene, propylene, tetramethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethylethylene, pentamethylene, 1, 1 Jimechiru Bok Rimechire emissions, 2, 2-dimethyl trimethylene, 1, be straight-chain or branched-chain alkylene groups such as 2-dimethyl trimethylene or to Kisamechire down group, preferably, Ji 1 over ⁇ 3 Chokukusariwaka properly is a branched chain alkylene group, more preferably a C 1 one C 3 linear alkylene group, still more preferably a methylene or ethylene group, and most preferably a methylene group It is.
- Aryl group which may be substituted with a group selected from the substituent group ⁇ ;” may be, for example, a phenyl or naphthyl group, preferably And a phenyl group.
- Aryl group is C 3 —.
- cycloalkyl preferably C 5 -C 6 cycloalkyl
- Ar represents “C 6 —C i.
- Aryl group substituted with a group selected from the group of substituents” it is preferably substituted with 1 to 4 groups selected from the group of substituents a C 6 —C 10 aryl groups, more preferably C 6 — substituted with one to three groups selected from the substituent group ⁇ .
- C 6 — which is an aryl group, more preferably substituted with 1 to 3 groups selected from the group consisting of a fluorine atom, a chlorine atom, methyl, ethyl, methoxy and ethoxy.
- Aryl group which is an aryl group, more preferably substituted with 1 to 3 groups selected from the group consisting of a fluorine atom, a chlorine atom, methyl, ethyl, methoxy and ethoxy.
- a 5- to 7-membered heteroaryl group containing 1 to 3 oxygen atoms and / or nitrogen atoms which may be substituted with a group selected from the substituent group ⁇ "
- a 5- to 7-membered heteroaryl group containing 1 to 3 oxygen atoms and / or nitrogen atoms '' is, for example, furyl, enyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, thiadiazolyl , Pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or azepinyl group, and preferably, furyl, chenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazoly
- Aryl preferably phenyl or C 3 —.
- C 5 - 0 6 cycloalkyl cycloalkyl
- it may be a condensed ring, such groups are, for example, indolyl, benzofuranyl, Benzoche alkenyl, quinolyl, isoquinolyl, quinazolinyl, tetrahydroquinolyl Or it may be a tetrahydroisoquinolyl group.
- Ar represents a ⁇ 5- to 7-membered heteroaryl group containing 1 to 3 sulfur, oxygen and / or nitrogen atoms substituted with a group selected from substituent group ⁇ '', Is a 5- to 7-membered heteroaryl group containing 1 to 3 sulfur atoms, oxygen atoms, and no or nitrogen atoms substituted with 1 to 3 groups selected from the substitution group ⁇ .
- protecting group for an amino group in the definition of R 1 is generally an amino group in the field of synthetic organic chemistry.
- the group is not particularly limited as long as it is a group used as a protecting group of and is of an acyl type (including sulfonyl type).
- acyl type including sulfonyl type.
- C i-C 6 alkoxy group in the definition of Substituent group ⁇ is a group in the gamma Omicron one C 6 alkyl group "is an oxygen atom is bonded, preferably, C i-C 4 linear or partial It is a branched-chain alkoxy group, more preferably a methoxy, ethoxy, propoxy, isopropoxy or butoxy group, particularly preferably a methoxy, ethoxy or propoxy group.
- halogen atom of the “halogen atom” in the definition of the substituent group ⁇ and the “phenyl group substituted with one or two halogen atoms” in the definition of R 4 are a fluorine atom, a chlorine atom, a bromine atom or an iodine atom. And is preferably a fluorine atom or a chlorine atom.
- R 3 - C 1 one C 4 of the "hydroxyl group, ⁇ C 4 alkoxy groups, C 1 one C 4 1 to 3 phenyl group substituted with a group selected from halogenated alkyl Le group and tetrazolyl
- the alkoxy group may be a linear or branched alkoxy group such as methoxy, ethoxy, propoxy, isopropoxy or butoxy, preferably methoxy, ethoxy or propoxy, more preferably Methoxy or ethoxy, particularly preferably methoxy.
- the 4- halogenated alkyl group is a group in which one or two or more hydrogen atoms of a C i-C 4 alkyl group are substituted with the above-mentioned “halogen atom”.
- Y is not particularly limited as long as it is a leaving group used in a nucleophilic substitution reaction.
- a halogen atom such as chlorine, bromine or iodine
- methoxycarbonyloxy or ethoxy Lower alkoxycarbonyl groups such as carbonyloxy; lower alkanesulfonyloxy groups such as methansulfonyloxy or esulfonyloxy; trifluoromethanesulfonyloxy or pentafluoromouth ethanesulfonyloxy
- a halogeno lower alkyl sulfonyloxy group such as, or an arylsulfonyloxy group such as benzenesulfonyloxy, p-toluenesulfonyloxy, 4-cyclobenzenebenzenesulfonyloxy or 4-12-trobenzenesulfonyloxy;
- a halogen atom such as chlorine, bro
- Ar is preferably a phenyl group which may be substituted with a group selected from a substituent group, more preferably a phenyl group or methyl, ethyl, methoxy, a fluorine atom and a chlorine atom. It is a phenyl group substituted with one or two groups selected from the group consisting of atoms, and particularly preferably a phenyl group.
- Substituent group ⁇ is preferably a C i -C 4 alkyl group, a C 4 alkoxy group and a halogen atom, and more preferably a fluorine atom, a chlorine atom, methyl, ethyl, methoxy and ethoxy. Become.
- R 2 is preferably a hydrogen atom, ethoxycarbonyl or tert-butoxycarbonyl, and particularly preferably a hydrogen atom.
- R 3 is preferably selected from the group consisting of hydroxyl, methoxy, ethoxy, trifluoromethyl, trichloromethyl, difluoromethyl, fluoromethyl and tetrazolyl
- Phenyl groups eg, 3,5-bis (trifluoromethyl) phenyl, 3,4,5-trimethoxyphenyl, 3-hydroxy-1,4,5-dimethoxyphenyl, 4-hydroxy 5-dimethoxyphenyl or 2-methoxy-1- (1-tetrazolyl) phenyl, more preferably 1 to 3 groups selected from the group consisting of methoxy, 1, trifluoromethyl, and tetrazolyl (E.g., 3,5-bis (trifluoromethyl) phenyl, 3,4,5-trimethoxyphenyl or 2-methoxy-5- (1-tetrazolyl) phenyl). Particularly preferred is 3,5-bis (trifluoromethyl) phenyl or 3,4,5-trimethoxyphenyl.
- R 4 is preferably a phenyl group substituted with one or two fluorine atoms or chlorine atoms, more preferably a phenyl group substituted with two fluorine atoms or chlorine atoms, More preferably, it is 3,4-difluorophenyl or 3,4-dichlorophenyl, and particularly preferably, 3,4-dichlorophenyl.
- n is preferably 2.
- preferred compounds are
- the present invention is implemented by the following steps.
- Oxidation of the compound of the above general formula (2) is carried out in an inert solvent in the presence of alcohol, water or a mixture of water and alcohol, and the presence of a complex of an optically active tartaric acid diester and titanium (IV) alkoxide. It is carried out under the action of an oxidizing agent.
- the inert solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting material.
- examples thereof include aliphatic hydrocarbons such as hexane, heptane or petroleum ether; benzene, toluene or Aromatic hydrocarbons such as xylene; acetyl ether, diisopropyl ether, dibutyl ether, tert-butyl methyl ether, tetrahydric ethers such as furan or dioxane; methyl acetate, ethyl acetate, propyl acetate Or esters such as butyl acetate; aliphatic halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride or dichlorobenzene; chlorobenzene, fluorobenzene, o-dichlorobenzene.
- Aromatic halogenated hydrocarbons such as m-dichlorobenzene, trichloromethylbenzene or trifluoromethylbenzene; amides such as N, N-dimethylformamide or N, N-dimethylacetamide; It can be an alcohol such as methanol, X ethanol, propyl alcohol, isopropyl alcohol, butyl alcohol or tert-butyl alcohol; or a nitrile such as acetonitrile, preferably an aromatic hydrocarbon, an ester.
- Aliphatic halogenated hydrocarbons or aromatic halogenated hydrocarbons More preferably, they are aliphatic halogenated hydrocarbons or aromatic halogenated hydrocarbons, and even more preferably, dichloroethane, cyclobenzene, o-dichlorobenzene, m-dichlorobenzene or trifluoromethyene. And most preferably, benzene or o-dichlorobenzene.
- the titanium (IV) alkoxide used to form the complex may be, for example, titanium (IV) methoxide, titanium (IV) ethoxide, titanium (IV) propoxide or titanium (IV) isopropoxide, preferably Titanium (IV) isopropoxide.
- the amount of the titanium (IV) 'alkoxide used is preferably from 0.01 to 0.4 equivalent, more preferably from 0.1 equivalent to 1 equivalent of the compound of the general formula (2). It is 0.5 to 0.2 equivalent.
- Optically active diesters used to form complexes include, for example, (+) mono- or (-) dimethyl mono-tartrate, (+)-or (-) getyl mono-tartrate, (+)-or ( -) Diisopropyl monotartrate, (+) — or (-) dibutyl tartrate, or (+) — or (-1) optically active diesters of tartaric acid such as di-tert-butyl tartrate; (+) — Or (I) ethyl monotartrate or (+) — or (I) — diisopropyl tartrate, and more preferably (+) — or (I) diisopropyl tartrate.
- the amount of the optically active diol used is preferably 1 to 10 equivalents, more preferably 2 to 5 equivalents, and more preferably 1 to 10 equivalents of titanium (IV) alkoxide. Is about 4 equivalents.
- Complexes of optically active tartaric acid diesters with titanium (IV) alkoxides are used in the presence of alcohol, water or a mixture of water and alcohol.
- the alcohol used here can be, for example, methanol, ethanol, propyl alcohol, isopropyl alcohol, butyl alcohol, tert-butyl alcohol or phenol, preferably methanol, ethanol, 'isopropyl alcohol or phenol. More preferably, it is isopropyl alcohol.
- the amount of the alcohol to be used is preferably 0.5 to 100 equivalents, more preferably 1 to 20 equivalents, per equivalent of titanium (IV) alkoxide.
- the amount of water used is preferably from 0.01 to 4 equivalents, more preferably from 0.02 to 2 equivalents, per equivalent of titanium (IV) alkoxide.
- the above-mentioned complex is preferably used in the presence of an alcohol (optimally, isopropyl alcohol), and is further used in an amount of 0.01 to 4 equivalents (preferably 0 to 1 equivalent) per equivalent of titanium (IV) alkoxide. 0.2 to 2 equivalents, more preferably 0.33 to 1.5 equivalents) of water.
- an alcohol optically, isopropyl alcohol
- an optically active tartaric acid diester preferably, (1) adding an optically active tartaric acid diester to an inert solvent, and then adding a titanium (IV) alkoxide, Then, alcohol, water or a mixture of water and alcohol is added, and finally the compound of the general formula (2) is added, or [2] an inert solvent containing the compound of the general formula (2) is added.
- the titanium (IV) alkoxide is added, followed by the addition of alcohol, water or a mixture of water and alcohol.
- the temperature at which this operation is performed is 0 to 100, preferably 15 to 30.
- the oxidizing agent used is cumene hydroperoxide or isopropyl cumyl hydroper And preferably cumene hydroperoxide.
- the amount of the oxidizing agent used is preferably 0.5 to 10 equivalents, more preferably 1 to 1.5 equivalents, per equivalent of the compound of the formula (2).
- the temperature at which the oxidizing agent is allowed to act is from 180 to 100 ° C., preferably from ⁇ 20 to 15 ° C.
- the reaction time when the oxidizing agent is applied varies depending on the reaction temperature and the like, but is usually 10 minutes to 20 hours', preferably 3 hours to 10 hours. After completion of the reaction, the target compound is collected from the reaction mixture according to a conventional method.
- the reaction mixture is appropriately neutralized, and if insolubles are present, they are removed by filtration, then water is added, the mixture is extracted with an immiscible organic solvent such as toluene, washed with water, etc., and the extract is washed. It is obtained by drying over anhydrous magnesium sulfate or the like and then distilling off the solvent. If necessary, the obtained compound can be separated and purified by a conventional method, for example, recrystallization or silica gel column chromatography.
- the target substance collected from the reaction mixture can be recrystallized, and the enantiomer excess can be increased by separation and purification using an optically active column [eg, CHRALCEL (trade name, manufactured by Daicel Chemical Industries, Ltd.)]. it can.
- an optically active column eg, CHRALCEL (trade name, manufactured by Daicel Chemical Industries, Ltd.)
- recrystallization is performed without removing the protecting group of the amino group, or (a) removing the protecting group of the amino group, and then (b) optically using a diastereomer method.
- the enantiomeric excess ratio can be increased.
- the removal of the protecting group for the amino group is carried out according to a well-known method, and for example, can be removed by treating with an acid or a base in an inert solvent.
- the solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting materials to some extent.
- the solvent include oils such as hexane, heptane, lignin and petroleum ether.
- Aliphatic hydrocarbons such as benzene, toluene or xylene; dichloromethane, chloroform, carbon tetrachloride, dichloroethane, cyclobenzene, o-cyclobenzene, m-dichlorobenzene, fluorobenzene, Halogenated hydrocarbons such as trichloromethylbenzene or trifluoromethylbenzene; ethers such as getyl ether, diisopropyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane or diethylene dalicol dimethyl ether Esters such as methyl acetate or ethyl acetate; alcohols such as methanol, ethanol,
- a mixed solvent of halogenated hydrocarbons, ethers, alcohols, fatty acids or water and the above-mentioned solvent more preferably halogenated hydrocarbons (particularly, benzene, o-dichloro Benzene, m-dichlorobenzene or trifluoromethylbenzene, ethers (especially tetrahydrofuran or dioxane), fatty acids (especially acetic acid), alcohols (especially methanol or ethanol), or a mixed solvent of water and the above solvent.
- the acid used can be, for example, hydrogen chloride, hydrochloric acid, sulfuric acid, phosphoric acid, hydrogen bromide, hydrobromic acid or trifluoroacetic acid, preferably hydrochloric acid, sulfuric acid, hydrobromic acid or trifluoroacetic acid It is.
- Bases used are, for example, alkali metal carbonates such as sodium carbonate, potassium carbonate or lithium carbonate; alkali metal bicarbonates such as sodium bicarbonate, potassium bicarbonate or lithium bicarbonate; Alkali metal hydrides such as lithium hydride, sodium hydride or hydrogen hydride; alkali metal hydroxides such as sodium hydroxide, hydroxide hydride or lithium hydroxide; sodium methoxide; Alkali metal alkoxides such as sodium ethoxide, potassium tert-butoxide or lithium methoxide; alkali metal thioalkoxides such as sodium thiomethoxide or sodium methoxide; hydrazine, methylamine, dimethylamine, ethyl Amin, triethylamine, triptylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-dimethylaminopyridine, N, N-dimethylaniline, N, N-getylani
- Organic bases preferably alkali metal carbonates (especially sodium carbonate or potassium carbonate) ', alkali metal hydroxides (especially sodium hydroxide or potassium hydroxide), alkali metal alkoxides (Especially sodium methoxide, sodium ethoxide or potassium tert-butoxide) or organic bases (especially hydrazine or methylamine).
- the reaction temperature varies depending on the starting compound, the solvent or the acid or base used, but is usually from 10 ° C to 15 ° C, preferably from 0 ° C to 100 ° C.
- reaction time varies depending on the starting compound, solvent or acid or base used, but is usually 5 minutes to 48 hours, preferably 10 minutes 7 to 15 hours.
- optical resolution by the diastereomer method is performed by using an optical resolution agent, for example, an aliphatic hydrocarbon such as hexane, heptane or petroleum ether; an aromatic hydrocarbon such as benzene, toluene or xylene; Ethers such as tyl ether, diisopropyl ether, dibutyl ether, tert-butyl methyl ether, tetrahydrofuran or dioxane; esters such as methyl acetate, ethyl acetate, propyl acetate or butyl acetate; methylene chloride, chloroform, Aliphatic halogenated hydrocarbons such as carbon tetrachloride or dichloroethane; alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol, butyl alcohol or tert-butyl alcohol; nitriles such as acetonitrile Ketones such as acetone;
- optical resolving agent to be used is not particularly limited as long as it is generally used as an optical resolving agent.
- (+)-tartaric acid, (+)-dibenzoyltartaric acid, ( ⁇ ) camphor-1 10-sulfonic acid or (+) — Mandelic acid is used, and more preferably, (+)-mandelic acid is used.
- Compound (2), which is a starting material in the method of the present invention is disclosed, for example, in US 61 59967 and US 6362179.
- the compound represented by the general formula (1) can be easily led to a neurokinin receptor antagonist by a method disclosed in, for example, WO 95/28389 and US Patent No. 6159967. More specifically, a neurokinin receptor antagonist can be produced by performing the reaction as described below. '
- compound (1) is compounded with compound (3).
- R 2 is a protecting group for an amino group, first remove R 2 and then react the obtained compound with compound (3).
- the removal of the protecting group for the amino group is carried out according to a well-known method, and for example, can be removed by treating with an acid or a base in an inert solvent.
- the solvent used is not particularly limited as long as it does not inhibit the reaction and dissolves a certain amount of the starting material.
- aliphatic hydrocarbons such as hexane, heptane, lignin or petroleum-ter
- aromatic hydrocarbons such as benzene, toluene or xylene
- dichloromethane, chloroform-form Such as carbon tetrachloride, dichloroethane, cyclobenzene, o-cyclobenzene, m-dichlorobenzene, fluorobenzene, trichloromethylbenzene or isopropyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane or diethylenedaricol dimethyl ether Ethers; esters such as methyl acetate or ethyl acetate; alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol or butyl alcohol;
- a mixed solvent of halogenated hydrocarbons, ethers, alcohols, fatty acids or water and the above-mentioned solvent more preferably halogenated hydrocarbons (particularly, benzene, o- Benzene, m-dichlorobenzene or trifluoromethylbenzene, ethers (particularly tetrahydrofuran or dioxane), fatty acids (particularly acetic acid), alcohols (particularly methanol or ethanol), or a mixed solvent of water and the above solvent It is. ''
- the acid used can be, for example, hydrogen chloride, hydrochloric acid, sulfuric acid, phosphoric acid, hydrogen bromide, hydrobromic acid or trifluoroacetic acid, preferably hydrochloric acid, sulfuric acid, hydrobromic acid or trifluoroacetic acid It is.
- Bases used are, for example, alkali metal carbonates such as sodium carbonate, potassium carbonate or lithium carbonate; alkali metal bicarbonates such as sodium bicarbonate, sodium bicarbonate or lithium bicarbonate; Alkali metal hydrides such as lithium hydride, sodium hydride or hydrogen hydride; alkali metal hydroxides such as sodium hydroxide, hydroxide hydride or lithium hydroxide; sodium methoxide; Alkali metal alkoxides such as sodium methoxide, potassium tert-butoxide or lithium methoxide; sodium thiome Lucali metal thioalkoxides; hydrazine, methylamine, dimethylamine, ethylamine, triethylamine, triptylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-dimethylaminopyridine, N, N-dimethylaniline, N, N-Getylaniline, 1,5-Diazapiciclo [4.3.0]
- organic bases such as Ndeco 7-ene (DBU), preferably alkali metal carbonates (especially sodium or potassium carbonate), alkali metal hydroxides (especially sodium hydroxide). Or potassium hydroxide), alkali metal alkoxides (particularly sodium methoxide, sodium ethoxide or potassium tert. Is a but-Kishido) or organic bases (particularly hydrazine or Mechiruamin).
- DBU Ndeco 7-ene
- alkali metal carbonates especially sodium or potassium carbonate
- alkali metal hydroxides especially sodium hydroxide
- potassium hydroxide alkali metal alkoxides
- organic bases particularly hydrazine or Mechiruamin.
- the reaction temperature varies depending on the starting compound, the solvent or the acid or base used, but it is generally 10 ° C to 150 ° C, preferably 0 ° C to 100 ° C.
- reaction time varies depending on the starting compound, solvent or acid or base used, but is usually 5 minutes to 48 hours, preferably 10 minutes to 15 hours.
- the inert solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting materials to some extent.
- examples include an aliphatic solvent such as hexane, heptane, lignin or petroleum ether. Hydrocarbons; aromatic hydrocarbons such as benzene, toluene or xylene; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, cyclobenzene or dichlorobenzene; ethyl formate, acetic acid Esters such as ethyl, propyl acetate, butyl acetate or getyl carbonate; ethers such as getyl ether, diisopropyl ether, tetrahydrofuran, dioxane, 1,2-dimethyloxetane or diethylene glycol dimethyl ether; acetone , Ethyl methyl ketone, isobuty
- the base used is not particularly limited as long as it is used as a base in a usual reaction.
- alkali metal carbonates such as sodium carbonate, potassium carbonate or lithium carbonate
- Alkaline earth metal carbonates such as sodium bicarbonate, lithium hydrogen carbonate or lithium bicarbonate
- alkaline metal hydrides such as lithium hydride, sodium hydride or potassium hydride
- Alkaline metal hydroxides such as sodium hydroxide, lithium hydroxide or lithium hydroxide
- alkaline earth metal hydroxides such as calcium hydroxide or barium hydroxide
- the reaction temperature can be, for example, from 0 ° C. to 150 ° C., and preferably from 20 ° C. to 120 ° C.
- the reaction time varies depending mainly on the reaction temperature, the starting compound, the reaction reagent or the type of the inert solvent used, but may be 30 minutes to 48 hours, preferably 1 hour to 12 hours.
- the target compound is collected from the reaction mixture according to a conventional method.
- it can be obtained by adding water to the reaction mixture, extracting with an immiscible organic solvent such as toluene, washing the extract with water or the like, drying over anhydrous magnesium sulfate or the like, and then distilling off the solvent.
- an immiscible organic solvent such as toluene
- the obtained compound can be separated and purified by a conventional method, for example, recrystallization, reprecipitation, or silica gel column chromatography.
- compound (4) may optionally be an acid (for example, the acid may be an inorganic acid such as hydrogen chloride, sulfuric acid or phosphoric acid; or an organic acid such as acetic acid, fumaric acid or succinic acid). And preferably treated with hydrogen chloride or fumaric acid) according to a conventional method, whereby a pharmacologically acceptable salt can be easily obtained.
- the acid may be an inorganic acid such as hydrogen chloride, sulfuric acid or phosphoric acid; or an organic acid such as acetic acid, fumaric acid or succinic acid.
- Both the enantiomeric excess and the diastereomeric excess in each Example are values based on analysis by high performance liquid chromatography (HPLC).
- the diastereomer excess was analyzed under the conditions of the following HPLC conditions (2).
- the HPLC for analyzing the composition of the reaction mixture was performed under the following conditions of the HPLC conditions (3) J.
- 7.47 ml (24.3 mniol) of titanium (IV) isopropoxide was added dropwise at room temperature, and the mixture was stirred at the same temperature for about 20 minutes.
- 7.48 ml (97.3 mmol) of isopropyl alcohol were added at room temperature, and the mixture was further stirred for about 20 minutes.
- tert-butyl spiro [benzo [c] thiophene 1 (3H), 411 piperidine] 9.70 g (31.8 mmol) of 1'-carboxylate and 70 ml of benzene are mixed.
- (1) 2.66 ml (12.7 mmol) of diisopropyl tartrate and 0.017 ml (0.96 mmol) of water were added at room temperature.
- 0.975 ml (3.18 mmol) of titanium (IV) isopropoxide was added dropwise at room temperature, and the mixture was stirred at the same temperature for about 20 minutes.
- tert-butyl spiro [benzo [c] thiophene-1 (3H), 4'-piperidine] — 1'-carboxylate 4.85 g (15.9 mmol) and 35 ml of benzene are mixed, and then (-) —2.66 ml (12.7 mmol) of diisopropyl tartrate were added at room temperature.
- 0.49 ml (1.59 mmol) of titanium (IV) isopropoxide was added dropwise at room temperature, and the mixture was stirred at the same temperature for about 20 minutes.
- 0.49 ml (6.35 mmol) of isopropyl alcohol was added at room temperature, and the mixture was further stirred for about 20 minutes.
- the compound having the general formula (1) is an important synthetic intermediate of an excellent neurokinin receptor antagonist (US Pat. No. 6,159,967), and according to the method of the present invention, the compound of the general formula (2) Is more economical and more economical than conventional methods (the methods described in US Pat. No. 6,159,967 and T. Nishi et al., Tetrahedron: Asymmetry, 1998, 9, 2567-2570). It can be obtained in high yield, and thus the method of the present invention is industrially useful.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002503520A CA2503520A1 (en) | 2002-10-24 | 2003-10-22 | Process for producing optically active sulfoxide |
EP03758784A EP1557420A4 (en) | 2002-10-24 | 2003-10-22 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE |
BR0315415-7A BR0315415A (pt) | 2002-10-24 | 2003-10-22 | Processo para preparar um composto |
AU2003275592A AU2003275592A1 (en) | 2002-10-24 | 2003-10-22 | Process for producing optically active sulfoxide |
US11/107,950 US20050209262A1 (en) | 2002-10-24 | 2005-04-14 | Process for producing optically active sulfoxide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002309653 | 2002-10-24 | ||
JP2002-309653 | 2002-10-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/107,950 Continuation US20050209262A1 (en) | 2002-10-24 | 2005-04-14 | Process for producing optically active sulfoxide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004037828A1 true WO2004037828A1 (ja) | 2004-05-06 |
Family
ID=32171014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013495 WO2004037828A1 (ja) | 2002-10-24 | 2003-10-22 | 光学活性なスルホキシドの製造法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050209262A1 (ja) |
EP (1) | EP1557420A4 (ja) |
JP (1) | JP2004161757A (ja) |
KR (1) | KR20050065613A (ja) |
CN (1) | CN1729196A (ja) |
AU (1) | AU2003275592A1 (ja) |
BR (1) | BR0315415A (ja) |
CA (1) | CA2503520A1 (ja) |
TW (1) | TW200409741A (ja) |
WO (1) | WO2004037828A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101323609B (zh) * | 2007-06-15 | 2013-05-01 | 成都福瑞生物工程有限公司 | 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法 |
US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
US8916565B2 (en) | 2011-02-02 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102055702B1 (ko) * | 2017-12-12 | 2019-12-13 | 주식회사 아미노로직스 | 광학 활성을 가진 2-옥틸글리신 에스터를 제조하는 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159967A (en) * | 1995-12-01 | 2000-12-12 | Sankyo Company, Limited | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use |
-
2003
- 2003-10-22 KR KR1020057006837A patent/KR20050065613A/ko not_active Application Discontinuation
- 2003-10-22 AU AU2003275592A patent/AU2003275592A1/en not_active Abandoned
- 2003-10-22 WO PCT/JP2003/013495 patent/WO2004037828A1/ja not_active Application Discontinuation
- 2003-10-22 BR BR0315415-7A patent/BR0315415A/pt not_active IP Right Cessation
- 2003-10-22 JP JP2003361552A patent/JP2004161757A/ja not_active Withdrawn
- 2003-10-22 EP EP03758784A patent/EP1557420A4/en not_active Withdrawn
- 2003-10-22 CA CA002503520A patent/CA2503520A1/en not_active Abandoned
- 2003-10-22 CN CNA2003801072100A patent/CN1729196A/zh active Pending
- 2003-10-23 TW TW092129379A patent/TW200409741A/zh unknown
-
2005
- 2005-04-14 US US11/107,950 patent/US20050209262A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159967A (en) * | 1995-12-01 | 2000-12-12 | Sankyo Company, Limited | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use |
Non-Patent Citations (4)
Title |
---|
KUBOTA HIROKAZU ET AL.: "Spiro-substituted piperidines as neurokinin receptor antagonists. II. Syntheses and NK2 receptor-antagonistic activities of N-(2-aryl-4-(spiro-substituted piperidin-1'-yl)butyl)carboxamides", KUBOTA HIROKAZU ET AL., vol. 46, no. 2, 1998, pages 242 - 254, XP002973896 * |
NISHI TAKAHIDE ET AL.: "Practical methods for the preparation of spiro(benzo(C)thiophenel(3H),4'-piperidine)-(2S)-oxide by resolution and asymmetric sulfoxidation", TETRAHEDRON ASYMMETRY, vol. 9, 1998, pages 2567 - 2570, XP004132749 * |
QUAGLIA WILMA ET AL.: "1'-Benzyl-3,4-dihydrospiro(2H-1-benzothiopyran-2,4'-piperidine)(Spipethiane), a potent and highly selective sigma 1 ligand", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 10, 1995, pages 1557 - 1560, XP002156379 * |
See also references of EP1557420A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101323609B (zh) * | 2007-06-15 | 2013-05-01 | 成都福瑞生物工程有限公司 | 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法 |
US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
US8916565B2 (en) | 2011-02-02 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
US9511067B2 (en) | 2011-02-02 | 2016-12-06 | Vertex Pharmaceuticals Incorporated | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels |
US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
US9181273B2 (en) | 2011-03-14 | 2015-11-10 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
Also Published As
Publication number | Publication date |
---|---|
AU2003275592A1 (en) | 2004-05-13 |
JP2004161757A (ja) | 2004-06-10 |
US20050209262A1 (en) | 2005-09-22 |
TW200409741A (en) | 2004-06-16 |
EP1557420A1 (en) | 2005-07-27 |
KR20050065613A (ko) | 2005-06-29 |
CA2503520A1 (en) | 2004-05-06 |
BR0315415A (pt) | 2005-08-16 |
CN1729196A (zh) | 2006-02-01 |
EP1557420A4 (en) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230040262A1 (en) | Stereoselective process for preparing substituted polycyclic pyridone derivatives | |
RU2518073C2 (ru) | Новое бициклическое гетероциклическое соединение | |
JP2800953B2 (ja) | 新規なイミド誘導体 | |
US11084784B2 (en) | ROR-gamma modulators and uses thereof | |
WO1996006837A1 (fr) | Isoxazoles | |
EP0927183B1 (en) | Spirocyclic metalloprotease inhibitors | |
PT1260512E (pt) | ''novos derivados de amida cíclicos'' | |
JP2017507960A (ja) | 新規クラスのミュー−オピオイド受容体アゴニスト | |
MX2015006458A (es) | Sintesis de derivados de isoxazolina espirociclicos. | |
US20050209262A1 (en) | Process for producing optically active sulfoxide | |
JP2008280297A (ja) | 12位ヘテロ置換ムチリン誘導体 | |
WO2011148956A1 (ja) | 縮合イミダゾール誘導体 | |
US20230278960A1 (en) | Novel acridinium salt and method for producing same | |
JP5697685B2 (ja) | 三環式抗生物質 | |
JP2010111684A (ja) | キラル2−メチル−4−保護化ピペラジンの立体選択的アルキル化 | |
EP1440075B1 (fr) | Nouveaux derives amides heteroaromatiques de 3beta-amino azabicyclooctane, leur procede de preparation et leurs applications en therapeutique | |
JP2007523160A (ja) | S−及びr−オメプラゾールの合成に有用な新規化合物並びにその製造方法 | |
CN112996566B (zh) | 用于治疗和预防乙型肝炎病毒感染的苯并二氢吡喃-4-酮衍生物 | |
EP1120415A1 (en) | Substituted isoxazolylthiophene compounds | |
ES2283781T3 (es) | Procedimiento para producir un compuesto de 1,2,3-triazol. | |
CA2489255A1 (en) | Process for producing cyclic thioether and synthetic intermediate thereof | |
RU2128178C1 (ru) | Пиперидинилзамещенные метаноантрацены и их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способы их получения | |
ES2285544T3 (es) | Derivados de pirrolo-pirazina utiles como moduladores de cb1. | |
ES2300854T3 (es) | Procedimiento estereoselectivo para la preparacion de clopidogrel. | |
JP2013136573A (ja) | 光学活性1−[3,5−ビス(トリフルオロメチル)フェニル]エタン誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 167929 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003758784 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11107950 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057006837 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2503520 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 949/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A72100 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057006837 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003758784 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |